Cambrex (NYSE:CBM) issued its quarterly earnings results on Thursday. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.17, Bloomberg Earnings reports. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The business had revenue of $182.28 million for the quarter, compared to analyst estimates of $181.39 million. During the same quarter in the prior year, the firm posted $1.23 earnings per share. The firm’s revenue for the quarter was up 2.5% compared to the same quarter last year. Cambrex updated its FY18 guidance to $2.80-3.03 EPS.
Cambrex (CBM) opened at $51.80 on Friday. Cambrex has a one year low of $42.55 and a one year high of $62.95. The stock has a market capitalization of $1,678.47, a price-to-earnings ratio of 16.87, a PEG ratio of 1.20 and a beta of 2.38.
CBM has been the topic of several research reports. Craig Hallum reaffirmed a “buy” rating and set a $60.00 price target (down previously from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. Zacks Investment Research raised Cambrex from a “strong sell” rating to a “hold” rating in a research note on Monday, January 15th. Finally, William Blair initiated coverage on Cambrex in a research note on Tuesday, January 16th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $60.00.
TRADEMARK VIOLATION WARNING: This report was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.com-unik.info/2018/02/10/cambrex-cbm-announces-earnings-results.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.